See more : Metro Bank PLC (MBNKF) Income Statement Analysis – Financial Results
Complete financial analysis of Amarin Corporation plc (AMRN) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Amarin Corporation plc, a leading company in the Biotechnology industry within the Healthcare sector.
- JULIEN AGRO INFRATECH LIMITED (JULIEN.BO) Income Statement Analysis – Financial Results
- JPMorgan Elect plc - Managed Cash (JPEC.L) Income Statement Analysis – Financial Results
- The Torrington Water Company (TORW) Income Statement Analysis – Financial Results
- Sagar Cements Limited (SAGCEM.BO) Income Statement Analysis – Financial Results
- AB Fagerhult (publ.) (0RQH.L) Income Statement Analysis – Financial Results
Amarin Corporation plc (AMRN)
About Amarin Corporation plc
Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, Germany, Canada, Lebanon, and the United Arab Emirates. Its lead product is VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. The company sells its products principally to wholesalers and specialty pharmacy providers. It has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa, the omega-3 acid, and eicosapentaenoic acid. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.
Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | 306.91M | 369.19M | 583.19M | 614.06M | 429.76M | 229.21M | 181.10M | 130.08M | 81.76M | 54.20M | 26.35M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 7.37M | 500.00K | 500.00K | 1.02M | 7.37M | 65.51M | 53.77M | 17.55M | 11.22M | 19.00M | 24.30M | 21.50M | 29.10M | 18.70M | 14.70M |
Cost of Revenue | 141.37M | 126.71M | 121.33M | 131.44M | 96.02M | 54.54M | 44.95M | 34.36M | 27.88M | 20.49M | 11.91M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 107.00K | 11.91M | 30.13M | 21.46M | 5.22M | 2.98M | 3.70M | 2.80M | 4.00M | 4.90M | 0.00 | 3.10M |
Gross Profit | 165.54M | 242.48M | 461.86M | 482.62M | 333.74M | 174.67M | 136.15M | 95.72M | 53.88M | 33.72M | 14.44M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 7.37M | 500.00K | 500.00K | 910.00K | -4.55M | 35.38M | 32.32M | 12.33M | 8.24M | 15.30M | 21.50M | 17.50M | 24.20M | 18.70M | 11.60M |
Gross Profit Ratio | 53.94% | 65.68% | 79.20% | 78.59% | 77.66% | 76.20% | 75.18% | 73.58% | 65.90% | 62.21% | 54.79% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 100.00% | 100.00% | 100.00% | 89.48% | -61.74% | 54.01% | 60.10% | 70.25% | 73.47% | 80.53% | 88.48% | 81.40% | 83.16% | 100.00% | 78.91% |
Research & Development | 22.22M | 30.41M | 29.31M | 38.96M | 34.39M | 55.90M | 47.16M | 49.98M | 51.06M | 50.33M | 72.75M | 58.96M | 21.60M | 28.01M | 17.84M | 12.95M | 12.11M | 17.19M | 8.31M | 3.48M | 5.44M | 6.22M | 4.14M | 5.75M | 7.44M | 19.80M | 19.80M | 0.00 | 0.00 | 0.00 | 0.00 |
General & Administrative | 88.61M | 118.80M | 141.86M | 112.66M | 323.62M | 180.18M | 112.04M | 93.40M | 93.07M | 79.35M | 121.25M | 57.79M | 22.56M | 17.09M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Selling & Marketing | 111.33M | 185.61M | 266.47M | 350.65M | 0.00 | 46.82M | 22.51M | 17.97M | 7.97M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A | 199.94M | 304.42M | 408.33M | 463.31M | 323.62M | 227.00M | 134.55M | 111.37M | 101.04M | 79.35M | 121.25M | 57.79M | 22.56M | 17.09M | 15.25M | 15.23M | 19.46M | 13.27M | 9.77M | 9.03M | 30.89M | 23.66M | 33.26M | 9.14M | 5.30M | 9.70M | 7.30M | 34.60M | 18.60M | 0.00 | 9.90M |
Other Expenses | 10.97M | -740.00K | -302.00K | 104.00K | -75.00K | -326.00K | 74.00K | -482.00K | -228.00K | 3.73M | -1.19M | -427.00K | 0.00 | 0.00 | -2.16M | 0.00 | 9.17M | 674.00K | 676.00K | -510.00K | -2.05M | 39.24M | 0.00 | -1.00K | 2.32M | 2.60M | 2.50M | 1.20M | 1.00M | 0.00 | 600.00K |
Operating Expenses | 233.13M | 334.83M | 437.64M | 502.27M | 358.02M | 282.90M | 181.71M | 161.35M | 152.10M | 129.67M | 194.00M | 116.75M | 44.16M | 45.10M | 30.93M | 28.18M | 40.73M | 31.13M | 18.76M | 12.00M | 34.27M | 69.12M | 37.40M | 14.89M | 15.05M | 32.10M | 29.60M | 35.80M | 19.60M | 0.00 | 10.50M |
Cost & Expenses | 374.50M | 461.54M | 558.97M | 633.72M | 454.03M | 337.44M | 226.66M | 195.71M | 179.98M | 150.16M | 205.91M | 116.75M | 44.16M | 45.10M | 30.93M | 28.18M | 40.73M | 31.13M | 18.76M | 12.11M | 46.19M | 99.25M | 58.85M | 20.11M | 18.03M | 35.80M | 32.40M | 39.80M | 24.50M | 0.00 | 13.60M |
Interest Income | 11.86M | 2.82M | 1.22M | 4.90M | 8.50M | 1.07M | 429.00K | 234.00K | 132.00K | 96.00K | 343.00K | 544.00K | 231.00K | 53.00K | 780.00K | 9.63M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Interest Expense | 8.00K | 15.00K | 129.00K | 2.61M | 6.63M | 7.80M | 9.77M | 18.44M | 20.05M | 18.48M | 34.18M | 18.09M | 1.00K | 19.00K | 8.23M | 2.14M | 6.46M | 0.00 | 1.80M | 0.00 | 0.00 | 29.46M | 0.00 | 0.00 | 0.00 | 24.40M | 800.00K | 0.00 | 0.00 | 0.00 | 0.00 |
Depreciation & Amortization | 2.97M | 3.09M | 2.86M | 2.05M | 862.56K | 667.87K | 715.59K | 777.59K | 812.00K | 844.00K | 892.00K | 449.00K | 76.00K | 63.00K | 582.00K | 251.00K | 386.00K | 795.00K | 810.00K | 754.00K | 671.00K | 8.29M | 21.22M | 2.42M | 2.32M | 2.60M | 2.50M | 1.20M | 1.00M | 0.00 | 600.00K |
EBITDA | -50.90M | -100.65M | 14.28M | -12.71M | -15.06M | -106.63M | -44.82M | -56.53M | -97.41M | -39.78M | -134.62M | -152.32M | -66.79M | -249.90M | -55.16M | -19.87M | -38.44M | -31.16M | -19.29M | -9.85M | -6.09M | -25.45M | 16.14M | -224.00K | -4.81M | -7.90M | -5.60M | -17.10M | 5.60M | 18.70M | 1.70M |
EBITDA Ratio | -16.59% | -24.45% | 4.31% | -2.39% | -3.69% | -47.36% | -24.49% | -50.82% | -120.42% | -170.16% | -681.23% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -437.07% | -6,280.80% | -3,358.80% | -3,309.93% | -732.53% | 6.42% | 29.96% | -2.85% | -27.11% | -8.95% | -15.64% | -87.44% | 16.15% | 100.00% | 9.52% |
Operating Income | -67.59M | -92.34M | 22.28M | -19.66M | -24.28M | -108.23M | -45.56M | -65.63M | -98.22M | -95.96M | -182.11M | -116.75M | -44.16M | -45.10M | -52.30M | -28.18M | -40.73M | -31.16M | -18.91M | -11.09M | -38.82M | -32.66M | -5.08M | -2.56M | -6.81M | -16.80M | -8.10M | -18.30M | 4.60M | 18.70M | 1.10M |
Operating Income Ratio | -22.02% | -25.01% | 3.82% | -3.20% | -5.65% | -47.22% | -25.15% | -50.45% | -120.14% | -177.03% | -691.08% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -553.06% | -6,232.20% | -3,781.60% | -1,090.66% | -527.10% | -49.86% | -9.44% | -14.59% | -60.71% | -88.42% | -33.33% | -85.12% | 15.81% | 100.00% | 7.48% |
Total Other Income/Expenses | 13.92M | 2.06M | 789.00K | 2.40M | 1.80M | -8.12M | -9.26M | -10.76M | -20.07M | 36.75M | 12.69M | -54.20M | -22.73M | -204.92M | -29.36M | 7.22M | -7.08M | 3.64M | -2.35M | 222.00K | 12.24M | -883.00K | -298.00K | 525.00K | -1.63M | -5.50M | -3.20M | 1.60M | 900.00K | 0.00 | 200.00K |
Income Before Tax | -53.67M | -103.81M | 11.29M | -17.26M | -22.48M | -116.35M | -54.82M | -76.38M | -118.29M | -59.20M | -169.42M | -170.07M | -66.61M | -250.09M | -59.76M | -20.70M | -39.03M | -27.72M | -19.41M | 11.35M | -26.58M | -33.55M | -4.71M | -2.22M | -10.15M | -30.10M | -11.30M | -16.70M | 5.50M | 0.00 | 1.30M |
Income Before Tax Ratio | -17.49% | -28.12% | 1.94% | -2.81% | -5.23% | -50.76% | -30.27% | -58.72% | -144.69% | -109.22% | -642.94% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -529.99% | -5,543.80% | -3,881.00% | 1,115.54% | -360.90% | -51.21% | -8.76% | -12.66% | -90.48% | -158.42% | -46.50% | -77.67% | 18.90% | 0.00% | 8.84% |
Income Tax Expense | 5.44M | 2.00M | 3.56M | 745.00K | 164.00K | 96.00K | 13.05M | 9.97M | -3.09M | -2.84M | -3.19M | 9.12M | 2.52M | -501.00K | -440.00K | -674.00K | -837.00K | -799.00K | -698.00K | 7.33M | -7.36M | 3.54M | 412.00K | 342.00K | -27.00K | 100.00K | 600.00K | -1.10M | 1.40M | 15.90M | 500.00K |
Net Income | -59.11M | -105.80M | 7.73M | -18.00M | -22.65M | -116.45M | -67.87M | -86.35M | -115.20M | -56.36M | -166.23M | -179.18M | -69.13M | -249.59M | -59.32M | -20.02M | -38.20M | -26.92M | -18.71M | 4.01M | -19.22M | -37.08M | -4.76M | 2.36M | 4.37M | -28.80M | -7.70M | -15.60M | 4.10M | 2.80M | 900.00K |
Net Income Ratio | -19.26% | -28.66% | 1.33% | -2.93% | -5.27% | -50.80% | -37.47% | -66.38% | -140.91% | -103.99% | -630.82% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -518.63% | -5,384.00% | -3,741.40% | 394.49% | -261.02% | -56.61% | -8.85% | 13.43% | 38.96% | -151.58% | -31.69% | -72.56% | 14.09% | 14.97% | 6.12% |
EPS | -0.15 | -0.26 | 0.02 | -0.05 | -0.07 | -0.39 | -0.25 | -0.41 | -0.64 | -0.32 | -1.03 | -1.24 | -0.53 | -2.49 | -1.40 | -0.91 | -4.08 | -3.35 | -4.63 | 1.72 | -11.24 | -39.71 | -0.67 | 6.42 | 2.90 | -19.29 | -52.00 | -110.00 | 31.00 | 20.00 | 8.00 |
EPS Diluted | -0.15 | -0.26 | 0.02 | -0.05 | -0.07 | -0.39 | -0.25 | -0.41 | -0.64 | -0.32 | -0.99 | -1.24 | -0.53 | -2.49 | -1.40 | -0.91 | -4.08 | -3.35 | -4.63 | 1.72 | -11.24 | -39.71 | -0.40 | 3.02 | 2.90 | -19.29 | -52.00 | -110.00 | 31.00 | 20.00 | 8.00 |
Weighted Avg Shares Out | 407.66M | 401.16M | 395.99M | 381.76M | 342.54M | 297.24M | 270.65M | 210.61M | 179.59M | 173.72M | 161.02M | 144.02M | 130.25M | 100.24M | 42.42M | 22.06M | 9.37M | 8.03M | 4.04M | 1.79M | 1.71M | 933.77K | 7.12M | 149.89K | 1.50M | 1.49M | 148.08K | 141.82K | 132.26K | 140.00K | 112.50K |
Weighted Avg Shares Out (Dil) | 407.66M | 401.16M | 402.48M | 381.76M | 342.54M | 297.24M | 270.65M | 211.87M | 180.65M | 173.82M | 167.07M | 144.02M | 130.25M | 100.24M | 42.42M | 22.06M | 9.37M | 8.03M | 4.04M | 1.79M | 1.71M | 933.77K | 12.04M | 842.09K | 1.50M | 1.49M | 148.08K | 141.82K | 132.26K | 140.00K | 112.50K |
Amarin Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
Amarin to Report Fourth Quarter and Full Year 2023 Financial Results and Host Conference on February 29, 2024
5 Biotech Stocks Likely to Outpace Q4 Earnings Estimates
Amarin Chairman & CEO Issue Letter to Shareholders
Amarin: Sarissa Is Giving Me Hope Again
Are Medical Stocks Lagging Amarin (AMRN) This Year?
Amarin (AMRN) Stock Rises on Stellar Q4 Preliminary Results
Why Amarin Stock Skyrocketed Today
Amarin Corporation plc (AMRN) CEO Pat Holt presents at 42nd Annual J.P. Morgan Healthcare Conference (Transcript)
Amarin stock soars on preliminary 4Q revenue guidance, share buyback plan
Source: https://incomestatements.info
Category: Stock Reports